This Glasgow Biotech's $46M Bet Could Change Kidney Disease Treatment

Jan de Vries · 2026-08-07

A small biotech company in Glasgow just secured a massive vote of confidence from some of the biggest names in healthcare investing. Mironid has closed a $46 million Series B financing round to push its lead drug candidate through clinical development for Autosomal Dominant Polycystic Kidney Disease (ADPKD). That's a serious chunk of change for a company tackling a disease that affects more than 12 million people worldwide. ### Why This Funding Round Matters The round was led by the Scottish National Investment Bank, with support from existing backers including Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. When you see that kind of syndicate come together, it's a strong signal that the science is worth paying attention to. Neil Wilkie, CEO of Mironid, put it plainly: "ADPKD is the most common hereditary kidney disorder, affecting over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60. Securing funding from such a high-calibre syndicate is a strong validator of our approach." ### The Science Behind the Hype Mironid spun out of the University of Strathclyde and Heriot-Watt University back in 2015, building on over three decades of research into PDE biology by Professor Miles Houslay. The company focuses on developing drug candidates for degenerative and rare genetic kidney diseases, along with major inflammatory diseases and cancer. The proceeds from this Series B will go toward advancing Mironid's first-in-class LoAc small molecule candidate for ADPKD patients. Here's what makes this approach different: - LoAc molecules directly target cyclic AMP (cAMP), a cellular signal active across all stages of the disease - The approach drives both cell proliferation and fluid secretion within cysts - Preclinical data shows significant efficacy and a favorable safety profile - The treatment could reduce cyst number and kidney volume ### A Potential Game-Changer for Patients ADPKD is caused predominantly by mutations in the PKD1 or PKD2 gene, leading to the uncontrolled growth of fluid-filled cysts in the kidneys and, in many cases, eventual kidney failure. Current treatment options are limited, and patients often face a grim prognosis. Mironid argues that by preventing new cyst formation and arresting the growth of existing cysts, its cAMP-modulating approach could offer a more durable treatment option with an improved side-effect profile compared with existing therapies. That's a big deal for a disease where patients currently have few good options. ### What's Next for Mironid Beyond ADPKD, Mironid's pipeline targets phosphodiesterase 4 (PDE4) enzymes, which play a key role in cell signaling pathways implicated in disease progression. Led by an industry-experienced management team, the company operates on a research-and-development-led model, funded through venture capital and strategic investment. Paul Callaghan, Investment Director at the Scottish National Investment Bank, said: "Mironid exemplifies Scotland's growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease. We are pleased to join a committed group of investors to support the company through this critical stage of development." The fresh capital follows an earlier Series A extension round that brought the company's total funding since inception to about $47 million. With this new funding in hand, Mironid is well-positioned to advance its lead candidate through clinical trials and, hopefully, bring a new treatment option to patients who desperately need one. For anyone following the biotech space, this is a company worth watching closely. The science is sound, the investor backing is strong, and the potential impact on patients' lives is enormous.